Navigation Links
NxStage Medical Announces Needle Supply Agreement with DaVita

LAWRENCE, Mass., Jan. 7 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it has signed a five-year agreement with DaVita, Inc. (NYSE: DVA) to continue to supply DaVita's dialysis centers with MasterGuard and ButtonHole safety needle sets, subject to certain terms and conditions. Safety needles are essential products used to access patients' blood during the vast majority of chronic dialysis therapy treatments. MasterGuard is the leading product in this market, and became part of NxStage's product portfolio through the recent acquisition of Medisystems.

DaVita and its predecessors have a long, successful history with Medisystems brand needles.

"We are very pleased to continue our long-standing relationship as DaVita's primary needle supplier," said Jeffrey H. Burbank, President & CEO of NxStage Medical. "Medisystems' high quality, innovative products was one of the key reasons we acquired the company last year. This new agreement with DaVita solidifies NxStage's position as a dialysis industry leader in-center, as well as in the critical care and home hemodialysis markets."

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, changes relating to customer demand for NxStage's needle and other products and other factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.


Stephanie Marks of NxStage Medical, Inc.,


Web site:

SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NxStage Medical to Present at the Piper Jaffray Healthcare Conference on November 27, 2007
2. Arbios Announces SEPET(TM) Manufacturing Agreement With NxStage Medical
3. NxStage(R) Medical to Report Third Quarter 2007 Financial Results on Friday, November 2nd
4. NxStage Medical Provides Update on Medisystems Acquisition
5. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
6. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
7. Triage study challenges notions of emergency medical response to disaster
8. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
9. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
10. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
11. Inverness Medical Innovations Acquires ParadigmHealth
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions ... over 5.5 million people each year. Especially those living in larger cities are affected ... based in one of the most pollution-affected countries globally - decided to take action. ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
(Date:10/9/2017)... Jupiter, FL (PRWEB) , ... October 09, 2017 , ... ... episode, scheduled to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on ... Agriculture industry is faced with the challenge of how to continue to feed a ...
Breaking Biology Technology:
(Date:4/19/2017)... , April 19, 2017 The ... vendor landscape is marked by the presence of several ... however held by five major players - 3M Cogent, ... companies accounted for nearly 61% of the global military ... companies in the global military biometrics market boast global ...
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
Breaking Biology News(10 mins):